VALOR-HCM
2022
A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy
In 112 patients with obstructive HCM referred for septal reduction therapy, mavacamten reduced the need to proceed with or remain eligible for septal reduction therapy compared with placebo.
Result
- Absolute difference
- 58.9 points
- NNT
- 2
difference58.995% CI 44.0-73.9 · P < 0.001
Absolute difference and NNT are derived from the event rates.
- Subtopic
- myosin inhibitor
- Design
- Double-blind placebo-controlled RCT, phase 3
- Relevance
- Supporting: context rather than must-know.
- Cited in
- ESC 2023 CMPAHA/ACC 2024 HCM
- Source
- Desai MY, et al. J Am Coll Cardiol. 2022;80(2):95-108.doi 10.1016/j.jacc.2022.04.048
Discussion & critique
Small, short-term surrogate endpoint (SRT eligibility/referral rather than actual procedures or hard outcomes). Demonstrated that mavacamten can defer or avoid invasive septal reduction in obstructive HCM.